Minimal clinically important differences in the EORTC QLQ-BN20 in patients with brain metastases

Introduction Quality of life (QOL) is an important treatment endpoint in advanced cancer patients with brain metastases. In clinical trials, statistically significant changes can be reached in a large enough population; however, these changes may not be clinically relevant.